Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual Meeting
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that the design of the ongoing phase I/II study of birinapant in combination with Keytruda® (pembrolizumab) in advanced cancer patients will be presented during the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, which will take place from 1-5 June 2018 in Chicago, USA. The poster presentation will be given by the study’s lead investigator, Prof. Russell J. Schilder, Director of the Medical Gynecologic Oncology Program at Thomas Jefferson University Hospital in Philadelphia, USA, as indicated below: